Why the study?
Does pretreatment with calcium antagonists prevent adrenaline-mediated myocardial and endothelial damage in preclinical models?
Does pretreatment with calcium antagonists prevent adrenaline-mediated myocardial and endothelial damage in preclinical models?
Calcium antagonists may protect against catecholamine-induced cardiotoxicity by preventing the generation of plasma-borne cytotoxic free radicals.
Calcium antagonists may blunt catecholamine cytotoxicity in rat models; hypothesis-generating, with no implications for human practice.
OBJECTIVE: To investigate the mechanism of calcium antagonist mediated cytoprotection against the damaging effects of adrenaline in vivo on cardiac myocytes and human endothelial cells from the umbilical vein. METHODS: Human endothelial cells cultured from the umbilical vein and isolated rat cardiac myocytes were treated with plasma from rats given adrenaline 30 minutes previously with pretreatment with calcium antagonists and without. The effect on indices of cell damage that suggest oxidation stress was determined. RESULTS: Pretreatment of rats with calcium antagonists before adrenaline administration largely inhibited the cytotoxic effects of their plasma on the two target cells used. Plasma taken from animals not pretreated with calcium antagonists caused release of oxidised glutathione from cells, a fall in intra-cellular reduced glutathione concentration, a fall in ATP production, and release of angiotensin converting enzyme from the endothelial cells. CONCLUSION: Calcium antagonists protect against the cardiotoxic effects of catecholamine by preventing the generation of plasma borne cytotoxic compounds, which are probably free radicals.
No takes yet. Share an insight, caveat, or question.
Noronha-Dutra et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: